MARKET OPPORTUNITIES

  • A Reimbursable Clinical Diagnostic Decision Support Service

Two independent market research surveys commissioned by Neuraldx of an unbiased statistically representative samples of USA and Australian Clinicians as to their attitudes towards the need for and adoption of technology which differentially diagnosed MDD from Bipolar with >80% accuracy and their likely use of technology such as EVestG™. >85% of respondents were extremely favourable to the approval of a validated solution.

Geo.jpg

  • CNS Drug Development Tool 

There are approximately 240 Pharma companies and 10,000 drug trial sites underway globally in respect of CNS disorders.

Initial application of EVestG™ is patient stratification and selection into trials to assist “Treating to Target”.

  • OH&S Corporate screening

    Post-Traumatic Stress Disorder (PTSD), MDD and Anxiety occurs in unacceptable levels in private and public entities such as Armed Services, Police, Emergency Services. Aviation and contact Sports.

  • Research Institutions

    There are 100 Australian institutions, university departments and centres researching the brain and 20,000 globally. Research Customers are prepared to pay for an validated instrument that objectively measures brain function and is conveniently accessible and affordable in their laboratories to purchase and operate. 

    Note – a CE certification only is required to sell to Research Institutions for R&D purposes ONLY